COX4 Polyclonal Antibody

货号：ES2035
价格：面议
点击：2109

产品介绍

抗体信息

应用	WB;IHC-p;IF/ICC;ELISA
反应种属	Human;Rat;Mouse;
别称	COX4I1; COX4; Cytochrome c oxidase subunit 4 isoform 1; mitochondrial; Cytochrome c oxidase polypeptide IV; Cytochrome c oxidase subunit IV isoform 1; COX IV-1

【仅供科学研究使用】

相关产品:

产品名称	点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody \|抗卡瑞利珠单抗中和重组抗体(靶标：卡瑞利珠单抗中和抗体)	564
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	367
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	573
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	319
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	447
Anti-Infliximab Non-Neutralizing Recombinant Antibody \|抗英夫利昔单抗非中和重组抗体(靶标：英夫利昔单抗非中和抗体)	601
Anti-Infliximab Non-Neutralizing Recombinant Antibody \|抗英夫利昔单抗非中和重组抗体(靶标：英夫利昔单抗非中和抗体)	538
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	646
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	497
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	299
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	446
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	339
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	578
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	504
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	470
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody\|抗埃罗妥珠单抗非中和重组抗体(靶标：埃罗妥珠单抗非中和抗体)	616
Anti-Elotuzumab Neutralizing Recombinant Antibody \|抗埃罗妥珠单抗中和重组抗体(靶标：埃罗妥珠单抗中和抗体)	281
Anti-Elotuzumab Neutralizing Recombinant Antibody \|抗埃罗妥珠单抗中和重组抗体(靶标：埃罗妥珠单抗中和抗体)	354
Anti-Oleclumab Neutralizing Recombinant Antibody \|抗奥乐克单抗中和重组抗体(靶标：奥乐克单抗中和抗体)	338
Anti-Oleclumab Neutralizing Recombinant Antibody \|抗奥乐克单抗中和重组抗体(靶标：奥乐克单抗中和抗体)	349

在线客服

QQ交谈

销售热线：
15898894496(同微信)
我要留言
周一至周五每天9:00-17:00